Joseph F Krebs, Age 6111413 Cotulla Dr, Austin, TX 78739

6391575, May 21, 2002

Mar 5, 1999

09/263590

Lawrence C. Fritz - Rancho Santa Fe CA
Joseph F. Krebs - San Diego CA

IDUN Pharmaceuticals, Inc. - San Diego CA

C12Q 137

435 23, 435219, 435 772

Provided are methods for detecting membrane derived apoptotic activity. In one embodiment, the present invention provides methods for identifying membrane derived caspase activity. In other embodiments, drug discovery methods are provided for screening compounds that inhibit or enhance membrane derived caspase activity. In the various embodiments, heavy membrane fractions are utilized for the screening methodologies described herein.

6762045, Jul 13, 2004

Mar 20, 2002

10/103448

Joseph F. Krebs - San Diego CA
Anupama Srinivasan - Carlsbad CA
Lawrence C. Fritz - Rancho Santa Fe CA
Joe C. Wu - San Diego CA

Idun Pharmaceuticals, Inc. - San Diego CA

C12N 964

435226, 435183, 435219, 435212, 4352523, 4353201, 435325, 435410, 435 6, 435348, 4352542, 536 231, 536 232, 536 235

Provided are isolated nucleic acids encoding a novel membrane derived caspase-3 and polypeptides expressed therefrom. In one embodiment, the nucleic acid expression vectors that produce membrane derived caspase-3 polypeptide may be introduced into host cells as a gene delivery vehicle. In other embodiments, methods are provided for treating pathological disorders caused by altered apoptosis, such as autoimmune disease, cancer, viral infections, and bacterial infections. Another aspect of the invention is the use of the isolated nucleic acid encoding membrane derived caspase-3 and polypeptides expressed therefrom as a means for promoting or inhibiting programmed cell death.

7595173, Sep 29, 2009

Oct 22, 2004

10/971444

Joseph F. Krebs - Austin TX, US
Paul S. Zorner - Carlsbad CA, US
Ian A. Tomlinson - Midland MI, US

Dow Global Technologies Inc. - Midland MI

C12P 21/06
C07H 21/04
C07K 5/06

435 691, 43525234, 435212, 435471, 530330, 530331, 536 232

The subject invention relates to a low cost method of producing peptides, including antimicrobial peptides (AMPs), by using microbes. The subject methods enable greatly improved yields of the peptide/AMP as compared to those heretofore known in the art. The subject methods also surprisingly enable the use of to produce AMPs and other peptides. There are several components of the subject invention, which can be used alone or in combination. The subject invention provides for the production of peptides/AMPs in concatemeric precursors. The subject invention also provides novel methods of assembling monomers into multimers, and of cleaving the multimers to yield active monomers. The subject invention also relates to the use of these multimers fused to carrier peptides to produce fusion proteins. Preferably, both the multimers and the fusion proteins (multimers with the carrier polypeptides) lack charge balancing. It has been surprisingly determined that it is not necessary to offset the positive charges of multiple copies of AMPs in multimeric constructs.

8058255, Nov 15, 2011

Jun 15, 2009

12/484948

Lance P. Ford - Austin TX, US
Joseph Krebs - Austin TX, US

Applied Biosystems, LLC - Carlsbad CA

A01N 43/04
A61K 31/70

514 44A

The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.

8637269, Jan 28, 2014

Jul 9, 2010

12/833580

Joseph Francis Krebs - Austin TX, US

Bioo Scientific Corporation - Austin TX

C12Q 1/34

435 18, 544203

Melamine is a common industrial chemical contaminant which should be absent from food and feed supplies due to melamine's toxicity. Provided is a method to assess the presence of melamine in samples prepared from compositions. The method may include using a microbial enzyme called melamine deaminase which hydrolyzes melamine to ammeline and ammonia. The method may include assessing the presence of any ammonia produced from an enzymatic reaction between the sample and the enzyme.

2002009, Jul 11, 2002

Jan 8, 2002

10/042484

Lawrence Fritz - Rancho Santa Fe CA, US
Joseph Krebs - San Diego CA, US

Idun Pharmaceuticals, Inc. - San Diego CA

C12Q001/37

435/023000

Provided are methods for detecting membrane derived apoptotic activity. In one embodiment, the present invention provides methods for identifying membrane derived caspase activity. In other embodiments, drug discovery methods are provided for screening compounds that inhibit or enhance membrane derived caspase activity. In the various embodiments, heavy membrane fractions are utilized for the screening methodologies described herein.

2002019, Dec 26, 2002

Mar 26, 2002

10/108929

Joseph Krebs - San Diego CA, US
Anupama Srinivasan - Carlsbad CA, US
Lawrence Fritz - Rancho Santa Fe CA, US
Joe Wu - San Diego CA, US

IDUN Pharmaceuticals, Inc. - San Diego CA

C12N009/64
C07H021/04
C12N001/18
C12N005/06
C12P021/02
C12N001/21

435/226000, 435/320100, 435/325000, 435/252300, 435/348000, 435/254200, 536/023200, 435/069100

Provided are isolated nucleic acids encoding a novel membrane derived caspase-3 and polypeptides expressed therefrom. In one embodiment, the nucleic acid expression vectors that produce membrane derived caspase-3 polypeptide may be introduced into host cells as a gene delivery vehicle. In other embodiments, methods are provided for treating pathological disorders caused by altered apoptosis, such as autoimmune disease, cancer, viral infections, and bacterial infections. Another aspect of the invention is the use of the isolated nucleic acid encoding membrane derived caspase-3 and polypeptides expressed therefrom as a means for promoting or inhibiting programmed cell death.

2006014, Jun 29, 2006

Dec 23, 2004

11/020560

Lance Ford - Austin TX, US
Joseph Krebs - Austin TX, US

A61K 48/00
C12Q 1/68
C07H 21/02

514044000, 435006000, 536023100

The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA.